nodes	percent_of_prediction	percent_of_DWPC	metapath
Meloxicam—PTGS2—urinary bladder cancer	0.29	1	CbGaD
Meloxicam—PGD—Methotrexate—urinary bladder cancer	0.146	0.314	CbGbCtD
Meloxicam—ABCC4—Fluorouracil—urinary bladder cancer	0.0732	0.157	CbGbCtD
Meloxicam—ABCC4—Methotrexate—urinary bladder cancer	0.0404	0.0866	CbGbCtD
Meloxicam—PTGS2—Cisplatin—urinary bladder cancer	0.0366	0.0784	CbGbCtD
Meloxicam—PTGS2—Etoposide—urinary bladder cancer	0.0359	0.077	CbGbCtD
Meloxicam—PTGS1—Etoposide—urinary bladder cancer	0.0303	0.065	CbGbCtD
Meloxicam—CYP3A4—Thiotepa—urinary bladder cancer	0.0262	0.0561	CbGbCtD
Meloxicam—CYP2C8—Fluorouracil—urinary bladder cancer	0.021	0.045	CbGbCtD
Meloxicam—CYP2C8—Etoposide—urinary bladder cancer	0.0175	0.0375	CbGbCtD
Meloxicam—CYP2C9—Fluorouracil—urinary bladder cancer	0.0146	0.0314	CbGbCtD
Meloxicam—CYP2C9—Cisplatin—urinary bladder cancer	0.0124	0.0266	CbGbCtD
Meloxicam—CYP3A4—Etoposide—urinary bladder cancer	0.0071	0.0152	CbGbCtD
Meloxicam—CYP3A4—Doxorubicin—urinary bladder cancer	0.00484	0.0104	CbGbCtD
Meloxicam—CYP2C9—urine—urinary bladder cancer	0.00271	0.0823	CbGeAlD
Meloxicam—PGD—prostate gland—urinary bladder cancer	0.00212	0.0644	CbGeAlD
Meloxicam—CYP3A4—urine—urinary bladder cancer	0.00207	0.0628	CbGeAlD
Meloxicam—PGD—seminal vesicle—urinary bladder cancer	0.0018	0.0545	CbGeAlD
Meloxicam—ABCC4—prostate gland—urinary bladder cancer	0.00151	0.0458	CbGeAlD
Meloxicam—PGD—smooth muscle tissue—urinary bladder cancer	0.0015	0.0456	CbGeAlD
Meloxicam—PGD—renal system—urinary bladder cancer	0.00145	0.0439	CbGeAlD
Meloxicam—PGD—urethra—urinary bladder cancer	0.00142	0.0431	CbGeAlD
Meloxicam—PGD—female reproductive system—urinary bladder cancer	0.00116	0.0352	CbGeAlD
Meloxicam—Lornoxicam—PTGS2—urinary bladder cancer	0.00115	0.41	CrCbGaD
Meloxicam—PGD—vagina—urinary bladder cancer	0.00105	0.0318	CbGeAlD
Meloxicam—ABCC4—renal system—urinary bladder cancer	0.00103	0.0312	CbGeAlD
Meloxicam—Tenoxicam—PTGS2—urinary bladder cancer	0.00102	0.365	CrCbGaD
Meloxicam—PTGS1—prostate gland—urinary bladder cancer	0.000889	0.027	CbGeAlD
Meloxicam—PTGS2—prostate gland—urinary bladder cancer	0.00085	0.0258	CbGeAlD
Meloxicam—ABCC4—female reproductive system—urinary bladder cancer	0.000825	0.025	CbGeAlD
Meloxicam—PTGS1—seminal vesicle—urinary bladder cancer	0.000752	0.0228	CbGeAlD
Meloxicam—CYP2C8—renal system—urinary bladder cancer	0.000748	0.0227	CbGeAlD
Meloxicam—PTGS2—seminal vesicle—urinary bladder cancer	0.000719	0.0218	CbGeAlD
Meloxicam—PGD—lymph node—urinary bladder cancer	0.000678	0.0206	CbGeAlD
Meloxicam—PTGS1—epithelium—urinary bladder cancer	0.000654	0.0198	CbGeAlD
Meloxicam—Piroxicam—PTGS2—urinary bladder cancer	0.000631	0.226	CrCbGaD
Meloxicam—PTGS1—smooth muscle tissue—urinary bladder cancer	0.00063	0.0191	CbGeAlD
Meloxicam—PTGS2—epithelium—urinary bladder cancer	0.000625	0.0189	CbGeAlD
Meloxicam—PTGS1—renal system—urinary bladder cancer	0.000606	0.0184	CbGeAlD
Meloxicam—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000602	0.0183	CbGeAlD
Meloxicam—CYP2C8—female reproductive system—urinary bladder cancer	0.000599	0.0182	CbGeAlD
Meloxicam—PTGS2—renal system—urinary bladder cancer	0.000579	0.0176	CbGeAlD
Meloxicam—PTGS2—urethra—urinary bladder cancer	0.000569	0.0173	CbGeAlD
Meloxicam—CYP2C8—vagina—urinary bladder cancer	0.000541	0.0164	CbGeAlD
Meloxicam—CYP2C9—female reproductive system—urinary bladder cancer	0.000532	0.0161	CbGeAlD
Meloxicam—CYP3A4—renal system—urinary bladder cancer	0.000506	0.0154	CbGeAlD
Meloxicam—PTGS1—female reproductive system—urinary bladder cancer	0.000485	0.0147	CbGeAlD
Meloxicam—ABCC4—lymph node—urinary bladder cancer	0.000482	0.0146	CbGeAlD
Meloxicam—PTGS2—female reproductive system—urinary bladder cancer	0.000464	0.0141	CbGeAlD
Meloxicam—PTGS1—vagina—urinary bladder cancer	0.000439	0.0133	CbGeAlD
Meloxicam—PTGS2—vagina—urinary bladder cancer	0.00042	0.0127	CbGeAlD
Meloxicam—CYP3A4—female reproductive system—urinary bladder cancer	0.000405	0.0123	CbGeAlD
Meloxicam—PTGS1—lymph node—urinary bladder cancer	0.000284	0.00861	CbGeAlD
Meloxicam—PTGS2—lymph node—urinary bladder cancer	0.000271	0.00823	CbGeAlD
Meloxicam—Pharyngitis—Epirubicin—urinary bladder cancer	9.16e-05	0.00059	CcSEcCtD
Meloxicam—Cardiac disorder—Methotrexate—urinary bladder cancer	9.15e-05	0.00059	CcSEcCtD
Meloxicam—Sweating—Doxorubicin—urinary bladder cancer	9.12e-05	0.000588	CcSEcCtD
Meloxicam—Urinary tract disorder—Epirubicin—urinary bladder cancer	9.11e-05	0.000587	CcSEcCtD
Meloxicam—Oedema peripheral—Epirubicin—urinary bladder cancer	9.09e-05	0.000586	CcSEcCtD
Meloxicam—Haematuria—Doxorubicin—urinary bladder cancer	9.07e-05	0.000584	CcSEcCtD
Meloxicam—Connective tissue disorder—Epirubicin—urinary bladder cancer	9.07e-05	0.000584	CcSEcCtD
Meloxicam—Urethral disorder—Epirubicin—urinary bladder cancer	9.05e-05	0.000583	CcSEcCtD
Meloxicam—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	8.99e-05	0.00058	CcSEcCtD
Meloxicam—Angiopathy—Methotrexate—urinary bladder cancer	8.95e-05	0.000576	CcSEcCtD
Meloxicam—Sinusitis—Doxorubicin—urinary bladder cancer	8.92e-05	0.000575	CcSEcCtD
Meloxicam—Immune system disorder—Methotrexate—urinary bladder cancer	8.91e-05	0.000574	CcSEcCtD
Meloxicam—Dizziness—Fluorouracil—urinary bladder cancer	8.9e-05	0.000574	CcSEcCtD
Meloxicam—Visual impairment—Epirubicin—urinary bladder cancer	8.89e-05	0.000573	CcSEcCtD
Meloxicam—Mediastinal disorder—Methotrexate—urinary bladder cancer	8.89e-05	0.000573	CcSEcCtD
Meloxicam—Agranulocytosis—Doxorubicin—urinary bladder cancer	8.88e-05	0.000572	CcSEcCtD
Meloxicam—Diarrhoea—Cisplatin—urinary bladder cancer	8.73e-05	0.000563	CcSEcCtD
Meloxicam—Erythema multiforme—Epirubicin—urinary bladder cancer	8.72e-05	0.000562	CcSEcCtD
Meloxicam—Alopecia—Methotrexate—urinary bladder cancer	8.71e-05	0.000561	CcSEcCtD
Meloxicam—Vomiting—Gemcitabine—urinary bladder cancer	8.71e-05	0.000561	CcSEcCtD
Meloxicam—Mental disorder—Methotrexate—urinary bladder cancer	8.64e-05	0.000557	CcSEcCtD
Meloxicam—Rash—Gemcitabine—urinary bladder cancer	8.64e-05	0.000556	CcSEcCtD
Meloxicam—Dermatitis—Gemcitabine—urinary bladder cancer	8.63e-05	0.000556	CcSEcCtD
Meloxicam—Eye disorder—Epirubicin—urinary bladder cancer	8.62e-05	0.000556	CcSEcCtD
Meloxicam—Hypersensitivity—Etoposide—urinary bladder cancer	8.62e-05	0.000555	CcSEcCtD
Meloxicam—Tinnitus—Epirubicin—urinary bladder cancer	8.6e-05	0.000554	CcSEcCtD
Meloxicam—Erythema—Methotrexate—urinary bladder cancer	8.58e-05	0.000553	CcSEcCtD
Meloxicam—Malnutrition—Methotrexate—urinary bladder cancer	8.58e-05	0.000553	CcSEcCtD
Meloxicam—Haemoglobin—Doxorubicin—urinary bladder cancer	8.58e-05	0.000553	CcSEcCtD
Meloxicam—Headache—Gemcitabine—urinary bladder cancer	8.58e-05	0.000553	CcSEcCtD
Meloxicam—Cardiac disorder—Epirubicin—urinary bladder cancer	8.56e-05	0.000552	CcSEcCtD
Meloxicam—Flushing—Epirubicin—urinary bladder cancer	8.56e-05	0.000552	CcSEcCtD
Meloxicam—Vomiting—Fluorouracil—urinary bladder cancer	8.56e-05	0.000552	CcSEcCtD
Meloxicam—Rhinitis—Doxorubicin—urinary bladder cancer	8.56e-05	0.000552	CcSEcCtD
Meloxicam—Hepatitis—Doxorubicin—urinary bladder cancer	8.54e-05	0.00055	CcSEcCtD
Meloxicam—Haemorrhage—Doxorubicin—urinary bladder cancer	8.54e-05	0.00055	CcSEcCtD
Meloxicam—Rash—Fluorouracil—urinary bladder cancer	8.49e-05	0.000547	CcSEcCtD
Meloxicam—Dermatitis—Fluorouracil—urinary bladder cancer	8.48e-05	0.000547	CcSEcCtD
Meloxicam—Pharyngitis—Doxorubicin—urinary bladder cancer	8.47e-05	0.000546	CcSEcCtD
Meloxicam—Headache—Fluorouracil—urinary bladder cancer	8.44e-05	0.000544	CcSEcCtD
Meloxicam—Urinary tract disorder—Doxorubicin—urinary bladder cancer	8.43e-05	0.000543	CcSEcCtD
Meloxicam—Oedema peripheral—Doxorubicin—urinary bladder cancer	8.41e-05	0.000542	CcSEcCtD
Meloxicam—Dysgeusia—Methotrexate—urinary bladder cancer	8.41e-05	0.000542	CcSEcCtD
Meloxicam—Asthenia—Etoposide—urinary bladder cancer	8.39e-05	0.000541	CcSEcCtD
Meloxicam—Connective tissue disorder—Doxorubicin—urinary bladder cancer	8.39e-05	0.000541	CcSEcCtD
Meloxicam—Angiopathy—Epirubicin—urinary bladder cancer	8.37e-05	0.000539	CcSEcCtD
Meloxicam—Urethral disorder—Doxorubicin—urinary bladder cancer	8.37e-05	0.000539	CcSEcCtD
Meloxicam—Immune system disorder—Epirubicin—urinary bladder cancer	8.33e-05	0.000537	CcSEcCtD
Meloxicam—Mediastinal disorder—Epirubicin—urinary bladder cancer	8.32e-05	0.000536	CcSEcCtD
Meloxicam—Back pain—Methotrexate—urinary bladder cancer	8.3e-05	0.000535	CcSEcCtD
Meloxicam—Pruritus—Etoposide—urinary bladder cancer	8.27e-05	0.000533	CcSEcCtD
Meloxicam—Arrhythmia—Epirubicin—urinary bladder cancer	8.24e-05	0.000531	CcSEcCtD
Meloxicam—Visual impairment—Doxorubicin—urinary bladder cancer	8.23e-05	0.00053	CcSEcCtD
Meloxicam—Alopecia—Epirubicin—urinary bladder cancer	8.15e-05	0.000525	CcSEcCtD
Meloxicam—Nausea—Gemcitabine—urinary bladder cancer	8.14e-05	0.000524	CcSEcCtD
Meloxicam—Vomiting—Cisplatin—urinary bladder cancer	8.12e-05	0.000523	CcSEcCtD
Meloxicam—Vision blurred—Methotrexate—urinary bladder cancer	8.09e-05	0.000521	CcSEcCtD
Meloxicam—Mental disorder—Epirubicin—urinary bladder cancer	8.08e-05	0.000521	CcSEcCtD
Meloxicam—Erythema multiforme—Doxorubicin—urinary bladder cancer	8.07e-05	0.00052	CcSEcCtD
Meloxicam—Rash—Cisplatin—urinary bladder cancer	8.05e-05	0.000519	CcSEcCtD
Meloxicam—Dermatitis—Cisplatin—urinary bladder cancer	8.04e-05	0.000518	CcSEcCtD
Meloxicam—Erythema—Epirubicin—urinary bladder cancer	8.03e-05	0.000518	CcSEcCtD
Meloxicam—Malnutrition—Epirubicin—urinary bladder cancer	8.03e-05	0.000518	CcSEcCtD
Meloxicam—Diarrhoea—Etoposide—urinary bladder cancer	8e-05	0.000516	CcSEcCtD
Meloxicam—Nausea—Fluorouracil—urinary bladder cancer	8e-05	0.000515	CcSEcCtD
Meloxicam—Eye disorder—Doxorubicin—urinary bladder cancer	7.98e-05	0.000514	CcSEcCtD
Meloxicam—Ill-defined disorder—Methotrexate—urinary bladder cancer	7.96e-05	0.000513	CcSEcCtD
Meloxicam—Tinnitus—Doxorubicin—urinary bladder cancer	7.96e-05	0.000513	CcSEcCtD
Meloxicam—Anaemia—Methotrexate—urinary bladder cancer	7.93e-05	0.000511	CcSEcCtD
Meloxicam—Flushing—Doxorubicin—urinary bladder cancer	7.92e-05	0.000511	CcSEcCtD
Meloxicam—Cardiac disorder—Doxorubicin—urinary bladder cancer	7.92e-05	0.000511	CcSEcCtD
Meloxicam—Flatulence—Epirubicin—urinary bladder cancer	7.92e-05	0.00051	CcSEcCtD
Meloxicam—Tension—Epirubicin—urinary bladder cancer	7.88e-05	0.000508	CcSEcCtD
Meloxicam—Dysgeusia—Epirubicin—urinary bladder cancer	7.87e-05	0.000507	CcSEcCtD
Meloxicam—Nervousness—Epirubicin—urinary bladder cancer	7.8e-05	0.000503	CcSEcCtD
Meloxicam—Back pain—Epirubicin—urinary bladder cancer	7.77e-05	0.000501	CcSEcCtD
Meloxicam—Angiopathy—Doxorubicin—urinary bladder cancer	7.75e-05	0.000499	CcSEcCtD
Meloxicam—Malaise—Methotrexate—urinary bladder cancer	7.74e-05	0.000499	CcSEcCtD
Meloxicam—Dizziness—Etoposide—urinary bladder cancer	7.73e-05	0.000498	CcSEcCtD
Meloxicam—Muscle spasms—Epirubicin—urinary bladder cancer	7.72e-05	0.000498	CcSEcCtD
Meloxicam—Immune system disorder—Doxorubicin—urinary bladder cancer	7.71e-05	0.000497	CcSEcCtD
Meloxicam—Vertigo—Methotrexate—urinary bladder cancer	7.71e-05	0.000497	CcSEcCtD
Meloxicam—Mediastinal disorder—Doxorubicin—urinary bladder cancer	7.69e-05	0.000496	CcSEcCtD
Meloxicam—Leukopenia—Methotrexate—urinary bladder cancer	7.68e-05	0.000495	CcSEcCtD
Meloxicam—Arrhythmia—Doxorubicin—urinary bladder cancer	7.63e-05	0.000491	CcSEcCtD
Meloxicam—Nausea—Cisplatin—urinary bladder cancer	7.58e-05	0.000489	CcSEcCtD
Meloxicam—Vision blurred—Epirubicin—urinary bladder cancer	7.57e-05	0.000488	CcSEcCtD
Meloxicam—Alopecia—Doxorubicin—urinary bladder cancer	7.54e-05	0.000486	CcSEcCtD
Meloxicam—Cough—Methotrexate—urinary bladder cancer	7.49e-05	0.000483	CcSEcCtD
Meloxicam—Mental disorder—Doxorubicin—urinary bladder cancer	7.48e-05	0.000482	CcSEcCtD
Meloxicam—Ill-defined disorder—Epirubicin—urinary bladder cancer	7.45e-05	0.00048	CcSEcCtD
Meloxicam—Convulsion—Methotrexate—urinary bladder cancer	7.44e-05	0.000479	CcSEcCtD
Meloxicam—Vomiting—Etoposide—urinary bladder cancer	7.44e-05	0.000479	CcSEcCtD
Meloxicam—Erythema—Doxorubicin—urinary bladder cancer	7.43e-05	0.000479	CcSEcCtD
Meloxicam—Malnutrition—Doxorubicin—urinary bladder cancer	7.43e-05	0.000479	CcSEcCtD
Meloxicam—Anaemia—Epirubicin—urinary bladder cancer	7.42e-05	0.000478	CcSEcCtD
Meloxicam—Rash—Etoposide—urinary bladder cancer	7.37e-05	0.000475	CcSEcCtD
Meloxicam—Dermatitis—Etoposide—urinary bladder cancer	7.37e-05	0.000475	CcSEcCtD
Meloxicam—Headache—Etoposide—urinary bladder cancer	7.33e-05	0.000472	CcSEcCtD
Meloxicam—Flatulence—Doxorubicin—urinary bladder cancer	7.32e-05	0.000472	CcSEcCtD
Meloxicam—Myalgia—Methotrexate—urinary bladder cancer	7.31e-05	0.000471	CcSEcCtD
Meloxicam—Arthralgia—Methotrexate—urinary bladder cancer	7.31e-05	0.000471	CcSEcCtD
Meloxicam—Tension—Doxorubicin—urinary bladder cancer	7.29e-05	0.00047	CcSEcCtD
Meloxicam—Dysgeusia—Doxorubicin—urinary bladder cancer	7.28e-05	0.000469	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	7.26e-05	0.000468	CcSEcCtD
Meloxicam—Malaise—Epirubicin—urinary bladder cancer	7.24e-05	0.000467	CcSEcCtD
Meloxicam—Discomfort—Methotrexate—urinary bladder cancer	7.22e-05	0.000465	CcSEcCtD
Meloxicam—Nervousness—Doxorubicin—urinary bladder cancer	7.22e-05	0.000465	CcSEcCtD
Meloxicam—Vertigo—Epirubicin—urinary bladder cancer	7.22e-05	0.000465	CcSEcCtD
Meloxicam—Syncope—Epirubicin—urinary bladder cancer	7.2e-05	0.000464	CcSEcCtD
Meloxicam—Leukopenia—Epirubicin—urinary bladder cancer	7.19e-05	0.000463	CcSEcCtD
Meloxicam—Back pain—Doxorubicin—urinary bladder cancer	7.19e-05	0.000463	CcSEcCtD
Meloxicam—Muscle spasms—Doxorubicin—urinary bladder cancer	7.15e-05	0.00046	CcSEcCtD
Meloxicam—Palpitations—Epirubicin—urinary bladder cancer	7.1e-05	0.000457	CcSEcCtD
Meloxicam—Confusional state—Methotrexate—urinary bladder cancer	7.06e-05	0.000455	CcSEcCtD
Meloxicam—Loss of consciousness—Epirubicin—urinary bladder cancer	7.06e-05	0.000455	CcSEcCtD
Meloxicam—Cough—Epirubicin—urinary bladder cancer	7.01e-05	0.000452	CcSEcCtD
Meloxicam—Anaphylactic shock—Methotrexate—urinary bladder cancer	7.01e-05	0.000451	CcSEcCtD
Meloxicam—Vision blurred—Doxorubicin—urinary bladder cancer	7e-05	0.000451	CcSEcCtD
Meloxicam—Convulsion—Epirubicin—urinary bladder cancer	6.96e-05	0.000448	CcSEcCtD
Meloxicam—Infection—Methotrexate—urinary bladder cancer	6.96e-05	0.000448	CcSEcCtD
Meloxicam—Nausea—Etoposide—urinary bladder cancer	6.95e-05	0.000448	CcSEcCtD
Meloxicam—Hypertension—Epirubicin—urinary bladder cancer	6.94e-05	0.000447	CcSEcCtD
Meloxicam—Ill-defined disorder—Doxorubicin—urinary bladder cancer	6.9e-05	0.000444	CcSEcCtD
Meloxicam—Nervous system disorder—Methotrexate—urinary bladder cancer	6.87e-05	0.000443	CcSEcCtD
Meloxicam—Anaemia—Doxorubicin—urinary bladder cancer	6.87e-05	0.000443	CcSEcCtD
Meloxicam—Thrombocytopenia—Methotrexate—urinary bladder cancer	6.86e-05	0.000442	CcSEcCtD
Meloxicam—Myalgia—Epirubicin—urinary bladder cancer	6.84e-05	0.000441	CcSEcCtD
Meloxicam—Arthralgia—Epirubicin—urinary bladder cancer	6.84e-05	0.000441	CcSEcCtD
Meloxicam—Anxiety—Epirubicin—urinary bladder cancer	6.81e-05	0.000439	CcSEcCtD
Meloxicam—Skin disorder—Methotrexate—urinary bladder cancer	6.8e-05	0.000438	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	6.79e-05	0.000438	CcSEcCtD
Meloxicam—Hyperhidrosis—Methotrexate—urinary bladder cancer	6.77e-05	0.000436	CcSEcCtD
Meloxicam—Discomfort—Epirubicin—urinary bladder cancer	6.76e-05	0.000435	CcSEcCtD
Meloxicam—Malaise—Doxorubicin—urinary bladder cancer	6.7e-05	0.000432	CcSEcCtD
Meloxicam—Dry mouth—Epirubicin—urinary bladder cancer	6.69e-05	0.000431	CcSEcCtD
Meloxicam—Vertigo—Doxorubicin—urinary bladder cancer	6.68e-05	0.00043	CcSEcCtD
Meloxicam—Syncope—Doxorubicin—urinary bladder cancer	6.67e-05	0.00043	CcSEcCtD
Meloxicam—Leukopenia—Doxorubicin—urinary bladder cancer	6.65e-05	0.000429	CcSEcCtD
Meloxicam—Confusional state—Epirubicin—urinary bladder cancer	6.61e-05	0.000426	CcSEcCtD
Meloxicam—Palpitations—Doxorubicin—urinary bladder cancer	6.57e-05	0.000423	CcSEcCtD
Meloxicam—Anaphylactic shock—Epirubicin—urinary bladder cancer	6.56e-05	0.000422	CcSEcCtD
Meloxicam—Oedema—Epirubicin—urinary bladder cancer	6.56e-05	0.000422	CcSEcCtD
Meloxicam—Hypotension—Methotrexate—urinary bladder cancer	6.55e-05	0.000422	CcSEcCtD
Meloxicam—Loss of consciousness—Doxorubicin—urinary bladder cancer	6.53e-05	0.000421	CcSEcCtD
Meloxicam—Infection—Epirubicin—urinary bladder cancer	6.51e-05	0.00042	CcSEcCtD
Meloxicam—Cough—Doxorubicin—urinary bladder cancer	6.49e-05	0.000418	CcSEcCtD
Meloxicam—Shock—Epirubicin—urinary bladder cancer	6.45e-05	0.000416	CcSEcCtD
Meloxicam—Convulsion—Doxorubicin—urinary bladder cancer	6.44e-05	0.000415	CcSEcCtD
Meloxicam—Nervous system disorder—Epirubicin—urinary bladder cancer	6.43e-05	0.000414	CcSEcCtD
Meloxicam—Thrombocytopenia—Epirubicin—urinary bladder cancer	6.42e-05	0.000414	CcSEcCtD
Meloxicam—Hypertension—Doxorubicin—urinary bladder cancer	6.42e-05	0.000413	CcSEcCtD
Meloxicam—Tachycardia—Epirubicin—urinary bladder cancer	6.4e-05	0.000412	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	6.38e-05	0.000411	CcSEcCtD
Meloxicam—Skin disorder—Epirubicin—urinary bladder cancer	6.37e-05	0.00041	CcSEcCtD
Meloxicam—Hyperhidrosis—Epirubicin—urinary bladder cancer	6.34e-05	0.000408	CcSEcCtD
Meloxicam—Insomnia—Methotrexate—urinary bladder cancer	6.34e-05	0.000408	CcSEcCtD
Meloxicam—Myalgia—Doxorubicin—urinary bladder cancer	6.33e-05	0.000408	CcSEcCtD
Meloxicam—Arthralgia—Doxorubicin—urinary bladder cancer	6.33e-05	0.000408	CcSEcCtD
Meloxicam—Anxiety—Doxorubicin—urinary bladder cancer	6.31e-05	0.000406	CcSEcCtD
Meloxicam—Paraesthesia—Methotrexate—urinary bladder cancer	6.29e-05	0.000405	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	6.28e-05	0.000405	CcSEcCtD
Meloxicam—Discomfort—Doxorubicin—urinary bladder cancer	6.25e-05	0.000403	CcSEcCtD
Meloxicam—Dyspnoea—Methotrexate—urinary bladder cancer	6.25e-05	0.000402	CcSEcCtD
Meloxicam—Somnolence—Methotrexate—urinary bladder cancer	6.23e-05	0.000401	CcSEcCtD
Meloxicam—Dry mouth—Doxorubicin—urinary bladder cancer	6.19e-05	0.000399	CcSEcCtD
Meloxicam—Dyspepsia—Methotrexate—urinary bladder cancer	6.17e-05	0.000397	CcSEcCtD
Meloxicam—Hypotension—Epirubicin—urinary bladder cancer	6.13e-05	0.000395	CcSEcCtD
Meloxicam—Confusional state—Doxorubicin—urinary bladder cancer	6.12e-05	0.000394	CcSEcCtD
Meloxicam—Decreased appetite—Methotrexate—urinary bladder cancer	6.09e-05	0.000392	CcSEcCtD
Meloxicam—Oedema—Doxorubicin—urinary bladder cancer	6.07e-05	0.000391	CcSEcCtD
Meloxicam—Anaphylactic shock—Doxorubicin—urinary bladder cancer	6.07e-05	0.000391	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	6.05e-05	0.00039	CcSEcCtD
Meloxicam—Fatigue—Methotrexate—urinary bladder cancer	6.04e-05	0.000389	CcSEcCtD
Meloxicam—Infection—Doxorubicin—urinary bladder cancer	6.03e-05	0.000388	CcSEcCtD
Meloxicam—Pain—Methotrexate—urinary bladder cancer	5.99e-05	0.000386	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	5.97e-05	0.000385	CcSEcCtD
Meloxicam—Shock—Doxorubicin—urinary bladder cancer	5.97e-05	0.000385	CcSEcCtD
Meloxicam—Nervous system disorder—Doxorubicin—urinary bladder cancer	5.95e-05	0.000383	CcSEcCtD
Meloxicam—Thrombocytopenia—Doxorubicin—urinary bladder cancer	5.94e-05	0.000383	CcSEcCtD
Meloxicam—Insomnia—Epirubicin—urinary bladder cancer	5.93e-05	0.000382	CcSEcCtD
Meloxicam—Tachycardia—Doxorubicin—urinary bladder cancer	5.92e-05	0.000381	CcSEcCtD
Meloxicam—Skin disorder—Doxorubicin—urinary bladder cancer	5.89e-05	0.00038	CcSEcCtD
Meloxicam—Paraesthesia—Epirubicin—urinary bladder cancer	5.89e-05	0.000379	CcSEcCtD
Meloxicam—Hyperhidrosis—Doxorubicin—urinary bladder cancer	5.86e-05	0.000378	CcSEcCtD
Meloxicam—Dyspnoea—Epirubicin—urinary bladder cancer	5.84e-05	0.000377	CcSEcCtD
Meloxicam—Somnolence—Epirubicin—urinary bladder cancer	5.83e-05	0.000376	CcSEcCtD
Meloxicam—Feeling abnormal—Methotrexate—urinary bladder cancer	5.77e-05	0.000372	CcSEcCtD
Meloxicam—Dyspepsia—Epirubicin—urinary bladder cancer	5.77e-05	0.000372	CcSEcCtD
Meloxicam—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5.73e-05	0.000369	CcSEcCtD
Meloxicam—Decreased appetite—Epirubicin—urinary bladder cancer	5.7e-05	0.000367	CcSEcCtD
Meloxicam—Hypotension—Doxorubicin—urinary bladder cancer	5.67e-05	0.000365	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	5.66e-05	0.000365	CcSEcCtD
Meloxicam—Fatigue—Epirubicin—urinary bladder cancer	5.65e-05	0.000364	CcSEcCtD
Meloxicam—Pain—Epirubicin—urinary bladder cancer	5.61e-05	0.000361	CcSEcCtD
Meloxicam—Constipation—Epirubicin—urinary bladder cancer	5.61e-05	0.000361	CcSEcCtD
Meloxicam—Urticaria—Methotrexate—urinary bladder cancer	5.57e-05	0.000359	CcSEcCtD
Meloxicam—Abdominal pain—Methotrexate—urinary bladder cancer	5.54e-05	0.000357	CcSEcCtD
Meloxicam—Body temperature increased—Methotrexate—urinary bladder cancer	5.54e-05	0.000357	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.53e-05	0.000356	CcSEcCtD
Meloxicam—Insomnia—Doxorubicin—urinary bladder cancer	5.49e-05	0.000354	CcSEcCtD
Meloxicam—Paraesthesia—Doxorubicin—urinary bladder cancer	5.45e-05	0.000351	CcSEcCtD
Meloxicam—Dyspnoea—Doxorubicin—urinary bladder cancer	5.41e-05	0.000348	CcSEcCtD
Meloxicam—Feeling abnormal—Epirubicin—urinary bladder cancer	5.4e-05	0.000348	CcSEcCtD
Meloxicam—Somnolence—Doxorubicin—urinary bladder cancer	5.39e-05	0.000347	CcSEcCtD
Meloxicam—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.36e-05	0.000345	CcSEcCtD
Meloxicam—Dyspepsia—Doxorubicin—urinary bladder cancer	5.34e-05	0.000344	CcSEcCtD
Meloxicam—Decreased appetite—Doxorubicin—urinary bladder cancer	5.27e-05	0.00034	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	5.24e-05	0.000337	CcSEcCtD
Meloxicam—Fatigue—Doxorubicin—urinary bladder cancer	5.23e-05	0.000337	CcSEcCtD
Meloxicam—Urticaria—Epirubicin—urinary bladder cancer	5.21e-05	0.000336	CcSEcCtD
Meloxicam—Constipation—Doxorubicin—urinary bladder cancer	5.19e-05	0.000334	CcSEcCtD
Meloxicam—Pain—Doxorubicin—urinary bladder cancer	5.19e-05	0.000334	CcSEcCtD
Meloxicam—Body temperature increased—Epirubicin—urinary bladder cancer	5.18e-05	0.000334	CcSEcCtD
Meloxicam—Abdominal pain—Epirubicin—urinary bladder cancer	5.18e-05	0.000334	CcSEcCtD
Meloxicam—Hypersensitivity—Methotrexate—urinary bladder cancer	5.16e-05	0.000333	CcSEcCtD
Meloxicam—Asthenia—Methotrexate—urinary bladder cancer	5.03e-05	0.000324	CcSEcCtD
Meloxicam—Feeling abnormal—Doxorubicin—urinary bladder cancer	5e-05	0.000322	CcSEcCtD
Meloxicam—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.96e-05	0.00032	CcSEcCtD
Meloxicam—Pruritus—Methotrexate—urinary bladder cancer	4.96e-05	0.000319	CcSEcCtD
Meloxicam—PGD—Disease—FGFR3—urinary bladder cancer	4.9e-05	0.000937	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	4.89e-05	0.000934	CbGpPWpGaD
Meloxicam—PGD—Metabolism—GPX1—urinary bladder cancer	4.86e-05	0.000929	CbGpPWpGaD
Meloxicam—Hypersensitivity—Epirubicin—urinary bladder cancer	4.83e-05	0.000311	CcSEcCtD
Meloxicam—Urticaria—Doxorubicin—urinary bladder cancer	4.82e-05	0.000311	CcSEcCtD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4.82e-05	0.00092	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—UGT2B7—urinary bladder cancer	4.81e-05	0.00092	CbGpPWpGaD
Meloxicam—Body temperature increased—Doxorubicin—urinary bladder cancer	4.8e-05	0.000309	CcSEcCtD
Meloxicam—Abdominal pain—Doxorubicin—urinary bladder cancer	4.8e-05	0.000309	CcSEcCtD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	4.79e-05	0.000916	CbGpPWpGaD
Meloxicam—Diarrhoea—Methotrexate—urinary bladder cancer	4.79e-05	0.000309	CcSEcCtD
Meloxicam—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	4.79e-05	0.000916	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	4.77e-05	0.000913	CbGpPWpGaD
Meloxicam—PGD—Metabolism—ERCC2—urinary bladder cancer	4.77e-05	0.000912	CbGpPWpGaD
Meloxicam—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	4.76e-05	0.00091	CbGpPWpGaD
Meloxicam—Asthenia—Epirubicin—urinary bladder cancer	4.7e-05	0.000303	CcSEcCtD
Meloxicam—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.7e-05	0.000898	CbGpPWpGaD
Meloxicam—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	4.67e-05	0.000893	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	4.67e-05	0.000892	CbGpPWpGaD
Meloxicam—Pruritus—Epirubicin—urinary bladder cancer	4.64e-05	0.000299	CcSEcCtD
Meloxicam—Dizziness—Methotrexate—urinary bladder cancer	4.63e-05	0.000299	CcSEcCtD
Meloxicam—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	4.55e-05	0.00087	CbGpPWpGaD
Meloxicam—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	4.53e-05	0.000866	CbGpPWpGaD
Meloxicam—PGD—Metabolism—MTHFR—urinary bladder cancer	4.49e-05	0.000858	CbGpPWpGaD
Meloxicam—Diarrhoea—Epirubicin—urinary bladder cancer	4.49e-05	0.000289	CcSEcCtD
Meloxicam—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.47e-05	0.000288	CcSEcCtD
Meloxicam—Vomiting—Methotrexate—urinary bladder cancer	4.45e-05	0.000287	CcSEcCtD
Meloxicam—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	4.43e-05	0.000846	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	4.42e-05	0.000845	CbGpPWpGaD
Meloxicam—Rash—Methotrexate—urinary bladder cancer	4.42e-05	0.000285	CcSEcCtD
Meloxicam—Dermatitis—Methotrexate—urinary bladder cancer	4.41e-05	0.000284	CcSEcCtD
Meloxicam—ABCC4—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	4.41e-05	0.000843	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	4.41e-05	0.000842	CbGpPWpGaD
Meloxicam—Headache—Methotrexate—urinary bladder cancer	4.39e-05	0.000283	CcSEcCtD
Meloxicam—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	4.38e-05	0.000837	CbGpPWpGaD
Meloxicam—Asthenia—Doxorubicin—urinary bladder cancer	4.35e-05	0.00028	CcSEcCtD
Meloxicam—Dizziness—Epirubicin—urinary bladder cancer	4.34e-05	0.000279	CcSEcCtD
Meloxicam—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	4.33e-05	0.000828	CbGpPWpGaD
Meloxicam—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.32e-05	0.000825	CbGpPWpGaD
Meloxicam—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	4.3e-05	0.000822	CbGpPWpGaD
Meloxicam—Pruritus—Doxorubicin—urinary bladder cancer	4.29e-05	0.000277	CcSEcCtD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	4.18e-05	0.0008	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GSTO2—urinary bladder cancer	4.18e-05	0.000798	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—NAT1—urinary bladder cancer	4.18e-05	0.000798	CbGpPWpGaD
Meloxicam—PGD—Disease—CREBBP—urinary bladder cancer	4.17e-05	0.000798	CbGpPWpGaD
Meloxicam—Vomiting—Epirubicin—urinary bladder cancer	4.17e-05	0.000269	CcSEcCtD
Meloxicam—Nausea—Methotrexate—urinary bladder cancer	4.16e-05	0.000268	CcSEcCtD
Meloxicam—ABCC4—Hemostasis—PLAU—urinary bladder cancer	4.16e-05	0.000795	CbGpPWpGaD
Meloxicam—Diarrhoea—Doxorubicin—urinary bladder cancer	4.15e-05	0.000267	CcSEcCtD
Meloxicam—Rash—Epirubicin—urinary bladder cancer	4.13e-05	0.000266	CcSEcCtD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	4.13e-05	0.00079	CbGpPWpGaD
Meloxicam—Dermatitis—Epirubicin—urinary bladder cancer	4.13e-05	0.000266	CcSEcCtD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.11e-05	0.000785	CbGpPWpGaD
Meloxicam—Headache—Epirubicin—urinary bladder cancer	4.11e-05	0.000265	CcSEcCtD
Meloxicam—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	4.09e-05	0.000782	CbGpPWpGaD
Meloxicam—Dizziness—Doxorubicin—urinary bladder cancer	4.01e-05	0.000258	CcSEcCtD
Meloxicam—PTGS1—Metabolism—PRSS3—urinary bladder cancer	3.99e-05	0.000762	CbGpPWpGaD
Meloxicam—Nausea—Epirubicin—urinary bladder cancer	3.89e-05	0.000251	CcSEcCtD
Meloxicam—PTGS2—Disease—SLC19A1—urinary bladder cancer	3.88e-05	0.000741	CbGpPWpGaD
Meloxicam—Vomiting—Doxorubicin—urinary bladder cancer	3.86e-05	0.000249	CcSEcCtD
Meloxicam—Rash—Doxorubicin—urinary bladder cancer	3.82e-05	0.000246	CcSEcCtD
Meloxicam—Dermatitis—Doxorubicin—urinary bladder cancer	3.82e-05	0.000246	CcSEcCtD
Meloxicam—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	3.82e-05	0.00073	CbGpPWpGaD
Meloxicam—Headache—Doxorubicin—urinary bladder cancer	3.8e-05	0.000245	CcSEcCtD
Meloxicam—PTGS2—Disease—PRSS3—urinary bladder cancer	3.78e-05	0.000722	CbGpPWpGaD
Meloxicam—PGD—Disease—RHOA—urinary bladder cancer	3.78e-05	0.000722	CbGpPWpGaD
Meloxicam—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	3.76e-05	0.000719	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	3.65e-05	0.000698	CbGpPWpGaD
Meloxicam—PGD—Metabolism—PPARG—urinary bladder cancer	3.64e-05	0.000695	CbGpPWpGaD
Meloxicam—PTGS2—Disease—HDAC4—urinary bladder cancer	3.61e-05	0.000689	CbGpPWpGaD
Meloxicam—Nausea—Doxorubicin—urinary bladder cancer	3.6e-05	0.000232	CcSEcCtD
Meloxicam—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	3.59e-05	0.000685	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	3.57e-05	0.000682	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.5e-05	0.00067	CbGpPWpGaD
Meloxicam—PGD—Metabolism—CREBBP—urinary bladder cancer	3.49e-05	0.000668	CbGpPWpGaD
Meloxicam—PGD—Disease—ERBB2—urinary bladder cancer	3.49e-05	0.000668	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	3.44e-05	0.000657	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—CREBBP—urinary bladder cancer	3.43e-05	0.000656	CbGpPWpGaD
Meloxicam—PGD—Disease—PTGS2—urinary bladder cancer	3.42e-05	0.000653	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	3.4e-05	0.00065	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	3.4e-05	0.00065	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—NAT1—urinary bladder cancer	3.4e-05	0.00065	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—IGF1—urinary bladder cancer	3.39e-05	0.000648	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.34e-05	0.000639	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	3.25e-05	0.000621	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.2e-05	0.000611	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—TYMP—urinary bladder cancer	3.19e-05	0.000609	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PRSS3—urinary bladder cancer	3.17e-05	0.000605	CbGpPWpGaD
Meloxicam—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.14e-05	0.0006	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	3.11e-05	0.000594	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—RHOA—urinary bladder cancer	3.1e-05	0.000593	CbGpPWpGaD
Meloxicam—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.1e-05	0.000592	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.1e-05	0.000592	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.06e-05	0.000585	CbGpPWpGaD
Meloxicam—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	3e-05	0.000573	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3e-05	0.000572	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.99e-05	0.000571	CbGpPWpGaD
Meloxicam—PGD—Disease—CDKN1A—urinary bladder cancer	2.99e-05	0.000571	CbGpPWpGaD
Meloxicam—PGD—Disease—PTEN—urinary bladder cancer	2.98e-05	0.00057	CbGpPWpGaD
Meloxicam—ABCC4—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.97e-05	0.000568	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	2.92e-05	0.000558	CbGpPWpGaD
Meloxicam—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	2.89e-05	0.000552	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—NAT2—urinary bladder cancer	2.88e-05	0.000551	CbGpPWpGaD
Meloxicam—PTGS2—Disease—LIG1—urinary bladder cancer	2.86e-05	0.000548	CbGpPWpGaD
Meloxicam—PGD—Metabolism—PTGS2—urinary bladder cancer	2.86e-05	0.000547	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.85e-05	0.000545	CbGpPWpGaD
Meloxicam—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.85e-05	0.000544	CbGpPWpGaD
Meloxicam—PGD—Disease—EP300—urinary bladder cancer	2.84e-05	0.000543	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	2.8e-05	0.000535	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.77e-05	0.00053	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	2.77e-05	0.000529	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—NAT1—urinary bladder cancer	2.77e-05	0.000529	CbGpPWpGaD
Meloxicam—PGD—Disease—SRC—urinary bladder cancer	2.76e-05	0.000528	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.72e-05	0.00052	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	2.64e-05	0.000505	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—IL2—urinary bladder cancer	2.6e-05	0.000498	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	2.58e-05	0.000492	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.54e-05	0.000485	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—TYMP—urinary bladder cancer	2.53e-05	0.000484	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	2.53e-05	0.000484	CbGpPWpGaD
Meloxicam—PGD—Metabolism—PTEN—urinary bladder cancer	2.5e-05	0.000477	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—RRM2—urinary bladder cancer	2.49e-05	0.000476	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.48e-05	0.000475	CbGpPWpGaD
Meloxicam—PGD—Disease—MYC—urinary bladder cancer	2.48e-05	0.000473	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.43e-05	0.000465	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.43e-05	0.000464	CbGpPWpGaD
Meloxicam—PGD—Disease—EGFR—urinary bladder cancer	2.42e-05	0.000463	CbGpPWpGaD
Meloxicam—PGD—Metabolism—EP300—urinary bladder cancer	2.38e-05	0.000455	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—EP300—urinary bladder cancer	2.34e-05	0.000447	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.31e-05	0.000442	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—ENO2—urinary bladder cancer	2.3e-05	0.000441	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—HPGDS—urinary bladder cancer	2.3e-05	0.000441	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.29e-05	0.000439	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.29e-05	0.000438	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—NAT2—urinary bladder cancer	2.29e-05	0.000437	CbGpPWpGaD
Meloxicam—PGD—Disease—KRAS—urinary bladder cancer	2.29e-05	0.000437	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	2.28e-05	0.000435	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—SRC—urinary bladder cancer	2.27e-05	0.000434	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—GSTT1—urinary bladder cancer	2.24e-05	0.000427	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.2e-05	0.000421	CbGpPWpGaD
Meloxicam—PTGS2—Disease—ENO2—urinary bladder cancer	2.18e-05	0.000418	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	2.15e-05	0.000411	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	2.1e-05	0.000401	CbGpPWpGaD
Meloxicam—PTGS2—Disease—RBX1—urinary bladder cancer	2.07e-05	0.000396	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.07e-05	0.000395	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—TYMP—urinary bladder cancer	2.06e-05	0.000394	CbGpPWpGaD
Meloxicam—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.04e-05	0.00039	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.98e-05	0.000378	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—RRM2—urinary bladder cancer	1.98e-05	0.000378	CbGpPWpGaD
Meloxicam—PGD—Disease—HRAS—urinary bladder cancer	1.95e-05	0.000372	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.92e-05	0.000368	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—KRAS—urinary bladder cancer	1.88e-05	0.00036	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—NAT2—urinary bladder cancer	1.86e-05	0.000356	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—NQO1—urinary bladder cancer	1.86e-05	0.000355	CbGpPWpGaD
Meloxicam—PTGS2—Disease—JAG1—urinary bladder cancer	1.85e-05	0.000354	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—HPGDS—urinary bladder cancer	1.83e-05	0.00035	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—ENO2—urinary bladder cancer	1.83e-05	0.00035	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.82e-05	0.000349	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.82e-05	0.000349	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.82e-05	0.000348	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.8e-05	0.000345	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GSTT1—urinary bladder cancer	1.77e-05	0.000339	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.75e-05	0.000334	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.68e-05	0.000321	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.68e-05	0.00032	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—TP53—urinary bladder cancer	1.67e-05	0.00032	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.67e-05	0.000319	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.61e-05	0.000308	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.61e-05	0.000307	CbGpPWpGaD
Meloxicam—ABCC4—Hemostasis—HRAS—urinary bladder cancer	1.6e-05	0.000306	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.57e-05	0.0003	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—GSTP1—urinary bladder cancer	1.55e-05	0.000296	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.52e-05	0.00029	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.5e-05	0.000287	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.5e-05	0.000287	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.49e-05	0.000285	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.49e-05	0.000285	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.48e-05	0.000283	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.47e-05	0.000282	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.44e-05	0.000276	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—TYMS—urinary bladder cancer	1.44e-05	0.000275	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—GSTM1—urinary bladder cancer	1.42e-05	0.000272	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—NCOR1—urinary bladder cancer	1.42e-05	0.000272	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.42e-05	0.000272	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.42e-05	0.000271	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.38e-05	0.000264	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—GPX1—urinary bladder cancer	1.36e-05	0.000261	CbGpPWpGaD
Meloxicam—PTGS2—Disease—NCOR1—urinary bladder cancer	1.35e-05	0.000258	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—ERCC2—urinary bladder cancer	1.34e-05	0.000256	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.31e-05	0.00025	CbGpPWpGaD
Meloxicam—PTGS2—Disease—ERCC2—urinary bladder cancer	1.27e-05	0.000243	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.26e-05	0.000241	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.25e-05	0.000239	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.23e-05	0.000235	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.21e-05	0.000232	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.21e-05	0.000232	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.2e-05	0.00023	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.2e-05	0.000229	CbGpPWpGaD
Meloxicam—PTGS2—Disease—MTHFR—urinary bladder cancer	1.19e-05	0.000228	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.19e-05	0.000227	CbGpPWpGaD
Meloxicam—PTGS2—Disease—TERT—urinary bladder cancer	1.19e-05	0.000227	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.18e-05	0.000225	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.16e-05	0.000223	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.16e-05	0.000221	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.14e-05	0.000219	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.13e-05	0.000216	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.13e-05	0.000216	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.11e-05	0.000211	CbGpPWpGaD
Meloxicam—PTGS2—Disease—FGFR3—urinary bladder cancer	1.09e-05	0.000209	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.08e-05	0.000207	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.06e-05	0.000203	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.02e-05	0.000195	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.02e-05	0.000194	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1e-05	0.000191	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1e-05	0.000191	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—MTHFR—urinary bladder cancer	9.99e-06	0.000191	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—CREBBP—urinary bladder cancer	9.8e-06	0.000187	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—NQO1—urinary bladder cancer	9.77e-06	0.000187	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.68e-06	0.000185	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.48e-06	0.000181	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—TYMS—urinary bladder cancer	9.3e-06	0.000178	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CREBBP—urinary bladder cancer	9.29e-06	0.000178	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	9.2e-06	0.000176	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	9.2e-06	0.000176	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—GPX1—urinary bladder cancer	8.81e-06	0.000168	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	8.65e-06	0.000165	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—RRM2—urinary bladder cancer	8.63e-06	0.000165	CbGpPWpGaD
Meloxicam—PTGS2—Disease—RHOA—urinary bladder cancer	8.41e-06	0.000161	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.26e-06	0.000158	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	8.15e-06	0.000156	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	8.13e-06	0.000155	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PPARG—urinary bladder cancer	8.1e-06	0.000155	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PTGS2—urinary bladder cancer	8.03e-06	0.000153	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—ENO2—urinary bladder cancer	7.99e-06	0.000153	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	7.99e-06	0.000153	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.88e-06	0.000151	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—CREBBP—urinary bladder cancer	7.78e-06	0.000149	CbGpPWpGaD
Meloxicam—PTGS2—Disease—ERBB2—urinary bladder cancer	7.78e-06	0.000149	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	7.75e-06	0.000148	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—TYMS—urinary bladder cancer	7.57e-06	0.000145	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	7.49e-06	0.000143	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	7.49e-06	0.000143	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—GPX1—urinary bladder cancer	7.17e-06	0.000137	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	7.04e-06	0.000135	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—PTEN—urinary bladder cancer	7e-06	0.000134	CbGpPWpGaD
Meloxicam—PTGS1—Metabolism—EP300—urinary bladder cancer	6.68e-06	0.000128	CbGpPWpGaD
Meloxicam—PTGS2—Disease—CDKN1A—urinary bladder cancer	6.65e-06	0.000127	CbGpPWpGaD
Meloxicam—PTGS2—Disease—PTEN—urinary bladder cancer	6.64e-06	0.000127	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	6.62e-06	0.000126	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PPARG—urinary bladder cancer	6.59e-06	0.000126	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NQO1—urinary bladder cancer	6.44e-06	0.000123	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	6.33e-06	0.000121	CbGpPWpGaD
Meloxicam—PTGS2—Disease—EP300—urinary bladder cancer	6.33e-06	0.000121	CbGpPWpGaD
Meloxicam—PTGS2—Disease—SRC—urinary bladder cancer	6.15e-06	0.000118	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—PTEN—urinary bladder cancer	5.56e-06	0.000106	CbGpPWpGaD
Meloxicam—PTGS2—Disease—MYC—urinary bladder cancer	5.51e-06	0.000105	CbGpPWpGaD
Meloxicam—PTGS2—Disease—EGFR—urinary bladder cancer	5.39e-06	0.000103	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	5.37e-06	0.000103	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PPARG—urinary bladder cancer	5.36e-06	0.000103	CbGpPWpGaD
Meloxicam—PTGS2—Metabolism—EP300—urinary bladder cancer	5.3e-06	0.000101	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	5.19e-06	9.91e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	5.15e-06	9.85e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—KRAS—urinary bladder cancer	5.1e-06	9.74e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.99e-06	9.55e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4.94e-06	9.44e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4.94e-06	9.44e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—GPX1—urinary bladder cancer	4.73e-06	9.04e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.64e-06	8.87e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—PTEN—urinary bladder cancer	4.52e-06	8.64e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.36e-06	8.34e-05	CbGpPWpGaD
Meloxicam—PTGS2—Disease—HRAS—urinary bladder cancer	4.33e-06	8.28e-05	CbGpPWpGaD
Meloxicam—CYP2C8—Metabolism—EP300—urinary bladder cancer	4.31e-06	8.24e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	4.22e-06	8.07e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—PTEN—urinary bladder cancer	3.68e-06	7.03e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.54e-06	6.76e-05	CbGpPWpGaD
Meloxicam—CYP2C9—Metabolism—EP300—urinary bladder cancer	3.51e-06	6.71e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.4e-06	6.5e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.78e-06	5.32e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.43e-06	4.64e-05	CbGpPWpGaD
Meloxicam—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.31e-06	4.42e-05	CbGpPWpGaD
